ES2999137T3 - Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens - Google Patents

Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens Download PDF

Info

Publication number
ES2999137T3
ES2999137T3 ES16803503T ES16803503T ES2999137T3 ES 2999137 T3 ES2999137 T3 ES 2999137T3 ES 16803503 T ES16803503 T ES 16803503T ES 16803503 T ES16803503 T ES 16803503T ES 2999137 T3 ES2999137 T3 ES 2999137T3
Authority
ES
Spain
Prior art keywords
dry eye
soft contact
eye
ophthalmic solution
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16803503T
Other languages
English (en)
Spanish (es)
Inventor
Yoshihiro Oshita
Hitoshi Nakazawa
Isao Matsuoka
Asuka Kamimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2999137T3 publication Critical patent/ES2999137T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES16803503T 2015-06-05 2016-06-03 Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens Active ES2999137T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015114596 2015-06-05
PCT/JP2016/066590 WO2016195072A1 (ja) 2015-06-05 2016-06-03 ソフトコンタクトレンズが装用されたドライアイ患者の眼に点眼されるように用いられることを特徴とするドライアイ治療剤

Publications (1)

Publication Number Publication Date
ES2999137T3 true ES2999137T3 (en) 2025-02-24

Family

ID=57441364

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16803503T Active ES2999137T3 (en) 2015-06-05 2016-06-03 Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens

Country Status (11)

Country Link
US (3) US10729712B2 (enExample)
EP (1) EP3305301B1 (enExample)
JP (5) JP2017002035A (enExample)
KR (2) KR20180014768A (enExample)
CN (2) CN107635565A (enExample)
CA (1) CA2987882A1 (enExample)
ES (1) ES2999137T3 (enExample)
HK (1) HK1245651A1 (enExample)
RU (1) RU2742032C2 (enExample)
TW (1) TW201707710A (enExample)
WO (1) WO2016195072A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119114152A (zh) * 2017-06-17 2024-12-13 株式会社Acenet 自由基产生催化剂、自由基的制造方法、氧化反应产物的制造方法、药剂和农畜产用药剂
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
KR20240049646A (ko) * 2019-08-27 2024-04-16 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
CN113712909A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种复方地夸磷索四钠滴眼液及其制备方法
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
CN115996705A (zh) * 2020-06-23 2023-04-21 株式会社泰俊制药 包含地夸磷索的眼用组合物
WO2022113970A1 (ja) * 2020-11-30 2022-06-02 学校法人近畿大学 涙液層破壊時間短縮型ドライアイ治療剤および該治療剤を含む点眼剤
KR102548710B1 (ko) * 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN114187994A (zh) * 2021-12-06 2022-03-15 上海泽充生物技术有限公司 一种提示干眼症患者定期滴眼并记录的系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029817A (en) * 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
AU721273B2 (en) * 1996-09-20 2000-06-29 Bausch & Lomb Incorporated Method and composition for rewetting contact lenses and relieving eye dryness
US20040214754A1 (en) * 2001-10-03 2004-10-28 Ellis Edward J. Ophthalmic preparation containing glycomacropeptide
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
KR101690816B1 (ko) 2009-06-25 2016-12-28 라이온 가부시키가이샤 안과용 조성물 및 백탁·침전 억제 방법
JP5640492B2 (ja) 2009-06-30 2014-12-17 ライオン株式会社 眼科用組成物及び白濁・沈殿抑制方法
EP3434257A1 (en) * 2010-07-29 2019-01-30 Allergan, Inc. Preservative free brimonidine and timolol solutions
CN103096929A (zh) * 2010-09-10 2013-05-08 参天制药株式会社 以组合p2y2受体激动剂和透明质酸或其盐为特征的干眼症治疗剂、干眼症的治疗方法、及干眼症治疗剂的应用
JP2012149057A (ja) * 2010-12-28 2012-08-09 Santen Pharmaceut Co Ltd ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法
KR102075173B1 (ko) * 2011-01-18 2020-02-07 센주 세이야꾸 가부시키가이샤 보존 효력을 갖는 브롬페낙 수성 액제 조성물
SG10201607872PA (en) * 2012-03-26 2016-11-29 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
JP5686454B1 (ja) * 2013-12-12 2015-03-18 株式会社メニコン コンタクトレンズ装着用液剤およびそれを用いたコンタクトレンズの屈折率向上方法
SG11201705138QA (en) * 2014-12-25 2017-07-28 Santen Pharmaceutical Co Ltd Aqueous ophthalmic solution

Also Published As

Publication number Publication date
KR20180014768A (ko) 2018-02-09
US10729712B2 (en) 2020-08-04
US20180147230A1 (en) 2018-05-31
EP3305301C0 (en) 2024-11-27
KR20200079572A (ko) 2020-07-03
JP2017002035A (ja) 2017-01-05
JP2025096568A (ja) 2025-06-26
US10918656B2 (en) 2021-02-16
RU2742032C2 (ru) 2021-02-01
US20200254000A1 (en) 2020-08-13
JP2024014996A (ja) 2024-02-01
RU2017145545A (ru) 2019-07-09
HK1245651A1 (en) 2018-08-31
WO2016195072A1 (ja) 2016-12-08
US20210128601A1 (en) 2021-05-06
RU2017145545A3 (enExample) 2019-11-21
EP3305301A1 (en) 2018-04-11
EP3305301B1 (en) 2024-11-27
TW201707710A (zh) 2017-03-01
EP3305301A4 (en) 2019-02-13
CN113143948A (zh) 2021-07-23
JP2021073289A (ja) 2021-05-13
CA2987882A1 (en) 2016-12-08
JP2022093383A (ja) 2022-06-23
CN107635565A (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
ES2999137T3 (en) Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens
JP7128243B2 (ja) 水性点眼液
EA026680B1 (ru) Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора p2yи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора p2yи гиалуроновой кислоты или ее соли
JP7614069B2 (ja) ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
ES2994624T3 (en) Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer
JP7089131B1 (ja) 塩化ポリドロニウムを含有する水性点眼液
JP7230169B2 (ja) ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
JP7419600B2 (ja) ポリヘキサメチレンビグアナイドまたはその塩を含有する水性点眼液
HK40051709A (en) Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens
HK1246642A1 (en) Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens
JP2022186865A (ja) アルキルジアミノエチルグリシンまたはその塩を含有する水性点眼液